Temporal Changes in Atrial Fibrillation and Atrial Flutter Prevalence in Patients with ESKD Following Arteriovenous Fistula Placement

Résumé fourni par la source

Background: End-stage kidney disease (ESKD) patients have a high burden of cardiovascular disease, including hypertension, congestive heart failure, and coronary artery disease, which are known risk factors for atrial fibrillation and atrial flutter (AF/AFL). While the prevalence and predictors of AF/AFL have been studied in various populations, their occurrence and evolution in patients with ESKD remains unclear. Methods: We conducted a retrospective cohort study in 196 consecutive ESKD patients who underwent arteriovenous (AV) fistula placement. The prevalence and predictors of AF/AFL were analyzed before and after AV fistula placement. The study was approved by the Institutional Review Board (IRB). Results: The study population included 40% females, 60.7+/-14.6 years old, with BMI 28.3+/-6.6 and histories of hypertension (HTN) in 91.3%, coronary artery disease (CAD) in 46.9%, atrial fibrillation in 35.2%, diabetes mellitus (DM) in 63.7%, and congestive heart failure (CHF) in 50%. The maximum time difference between the first and the second ECGs was 137 months, with a mean of 34+/-27 months. At baseline, patients with AF/AFL were significantly older (p<0.001) and had a prior history of AF/AFL (p<0.001), while traditional arrhythmia risk factors, e.g. HTN, CAD, DM, or CHF were not associated with arrhythmia. During the study interval, ESKD patients experienced a 3-fold increase in the prevalence of AF/AFL after AV fistula placement, from 4% on baseline to 11% on the follow-up ECGs (p<0.001). At the follow-up and after AV fistula placement, none of the traditional AF/AFL risk factors were linked with arrhythmia. Conclusion: Prevalence of AF/AFL is significantly increased in ESKD patients following AV fistula placement. Traditional risk AF/AFL predictors do not appear to be important in these ESKD patients. Further studies of effects of AV fistula placement on arrhythmia are warranted in ESKD patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.